carboprost tromethamine (Rx)

Brand and Other Names:Hemabate

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 250mcg/mL

Abortion

Initial: 250 mcg IM; THEN repeat PRN q1.5-3.5hr OR

An initial, optional test dose of 100 mcg IM; THEN increase dose to 500 mcg if response is inadequate with 250 mcg doses

No more than 1200 mcg total dose or 2 days of continuous administration

Refractory Postpartum Uterine Bleeding

Initial 250 mcg IM, repeat PRN q15-90min

No more than 2000 mcg or 8 doses

Not applicable

Next:

Interactions

Interaction Checker

and carboprost tromethamine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (2)

                • eluxadoline

                  eluxadoline increases levels of carboprost tromethamine by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates.

                • oxytocin

                  carboprost tromethamine increases effects of oxytocin by pharmacodynamic synergism. Use Caution/Monitor.

                Minor (0)

                  Previous
                  Next:

                  Adverse Effects

                  Frequency Not Defined

                  Effects due to increased smooth muscle contractility most common

                  Nausea (1/3 patients), Vomiting (~2/3 patients)

                  Diarrhea (~2/3 patients)

                  Nervousness

                  Epistaxis

                  Sleep disorder

                  Hyperthermia

                  Flushing

                  Asthma

                  Wheezing

                  Coughing

                  Chest pain

                  Flushing

                  Hypertension

                  Syncope

                  Palpation

                  Tachycardia

                  Chest tightness

                  Anxiety

                  Chills/shivering

                  Dizziness

                  Drowsiness

                  Dystonia

                  Faintness

                  Headache

                  Lethargy

                  Lightheadedness

                  Nervousness

                  Sleep disturbance

                  Temperature elevation

                  Vasovagal syndrome

                  Vertigo

                  Rash

                  Breast tenderness

                  Dysmenorrhea-like pain

                  Endometritis

                  Hot flashes

                  Thyroid storm

                  Gagging/retching

                  Drowsiness

                  Dry throat

                  Choking sensation

                  Thirst

                  Taste alterations

                  Perforated uterus

                  Posterior cervical perforation

                  Urinary tract infection

                  Uterine bleeding (excessive)

                  Uterine rupture

                  Uterine sacculation

                  Local: injection site pain

                  Backache

                  Leg cramps

                  Muscular pain

                  Parethesia

                  Torticollis

                  Weakness

                  Blurred vision

                  Eye pain

                  Eyelid twitching

                  Tinnitus

                  Cough

                  Bronchospasm

                  Dyspnea

                  Hyperventilation

                  Pulmonary edema

                  Respiratory distress

                  Upper respiratory tract infection

                  Wheezing

                  Diaphoresis

                  Hiccups

                  Retained placental fragment

                  Septic shock

                  Previous
                  Next:

                  Warnings

                  Black Box Warning

                  Potent oxytocic agent; use strict aderence to recommended dosing

                  Only medically-trained personnel should administer the product in a hospital setting that can provide immediate care and acute surgical facilities

                  Contraindications

                  Hypersensitivity

                  Acute pelvic inflammatory disease

                  Active cardiac, pulmonary, renal or hepatic disease

                  Cautions

                  History of glaucoma or raised IOP

                  Asthma, hypertension/hypotension, cardiovascular disease

                  Transient fever observed with treatment possibly as a result of carboprost's effect on hypothalamic thermoregulation

                  Caution in patients with anemia, jaundice, renal impairment, hepatic impairment diabetes or epilepsy

                  To decrease GI side effects pretreatment or concomitant use with antiemetic and antidiarrheal agents recommended

                  Not for IV

                  Rare cases of cardiovascular collapse reported with prostaglandins

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: C

                  Lactation: Excretion in milk unknown

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Inhibits or stimulates smooth muscle contraction, which results in expulsion of the products of conception and is used to induce abortion between 13-20 weeks of pregnancy; inhibits release of norepinephrine or modulates its effects at neuroeffector sites

                  Pharmacokinetics

                  Peak plasma time: 20-30 min

                  Concentration: 1-1.6 ng/mL

                  Half-life: 3 hr

                  Protein bound: None

                  Excretion: Urine

                  Previous
                  Next:

                  Images

                  BRAND FORM. UNIT PRICE PILL IMAGE
                  Hemabate intramuscular
                  -
                  250 mcg/mL solution
                  Hemabate intramuscular
                  -
                  250 mcg/mL solution
                  carboprost tromethamine intramuscular
                  -
                  250 mcg/mL vial

                  Copyright © 2010 First DataBank, Inc.

                  Previous
                  Next:

                  Patient Handout

                  Patient Education
                  carboprost tromethamine intramuscular

                  NO MONOGRAPH AVAILABLE AT THIS TIME

                  USES: Consult your pharmacist.

                  HOW TO USE: Consult your pharmacist.

                  SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

                  PRECAUTIONS: Consult your pharmacist.

                  DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

                  OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

                  NOTES: No monograph available at this time.

                  MISSED DOSE: Consult your pharmacist.

                  STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

                  Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.

                  IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  Additional Offers
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.